Pyxis Oncology, Inc.
PYXS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $3 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $3 | $0 | $0 |
| % Margin | – | 100% | – | – |
| R&D Expenses | $18 | $17 | $17 | $14 |
| G&A Expenses | $6 | $5 | $6 | $5 |
| SG&A Expenses | $5 | $5 | $6 | $5 |
| Sales & Mktg Exp. | -$1 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $21 |
| Operating Expenses | $23 | $23 | $23 | $40 |
| Operating Income | -$23 | -$20 | -$23 | -$40 |
| % Margin | – | -700.4% | – | – |
| Other Income/Exp. Net | $1 | $2 | $2 | $2 |
| Pre-Tax Income | -$22 | -$18 | -$21 | -$38 |
| Tax Expense | $0 | $0 | $0 | -$2 |
| Net Income | -$22 | -$18 | -$21 | -$36 |
| % Margin | – | -650.9% | – | – |
| EPS | -0.35 | -0.3 | -0.35 | -0.58 |
| % Growth | -16.7% | 14.3% | 39.7% | – |
| EPS Diluted | -0.35 | -0.3 | -0.35 | -0.58 |
| Weighted Avg Shares Out | 63 | 62 | 61 | 61 |
| Weighted Avg Shares Out Dil | 63 | 62 | 61 | 61 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$21 | -$19 | -$22 | -$19 |
| % Margin | – | -681.4% | – | – |